Nonspecific spermatoxic vaccine and process of producing same



r tested Dec. 28, 1937- Y UNITED STATES PATENT OFFICE 1 nonsracrr'rc SPERMATOXIC VACCINE AND PROCESS or PRODUCING'SAME Morris J. Baskin, Denver, Colo.

- No Drawing. Application July 6, 1935,

' Serial No. 30,162

12 Claims. (Cl. 167- 18) invention relates to sperm andseminal to within the range of fifty to one hundred dedeterminants, spermatoxic vaccines and the like grees centigrade. c and particularly to such a product which is non-- The mixture isthen centrifuged and the superspecific and to a process of producing the same. natent fluid retained, discarding the sediment.

An object of the invention is the provision of To the retained fluid there is added an antiseptic 6 a testicular product adapted for use non-speciflsuch, for example, as sodium ethyl mercurithiocally as a. sperm and seminal determinant and salicylate (merthiolate) to make a solution apspermatoxic vaccine. proximately one-five-thousandth (1/5000); Then A further object is the provision of aprocess a preservative, such as chloretone or phenol, is

1 of producing such a product and especially the added to make an approximately five-tenths per? a rendering of the'same non-specific. cent (5%) solution.

7 produces in her a' condition of immunization to V 45 lows: From the testicular structure of mature More particularly, an object of the invention The solution thus producedwill test or assay as is he production, from materials obtained from follows, viz, inject 1 c. 0. into female rats at weekly the lower animals, of a determinant for human intervals for three doses. One week after last '15 sperm and semen and usuable as a vaccine or 1 dose withdraw blood from the heart of rat. A is antigen in vaccination of human female to proprecipitant test will be positive for spermatozoa.

duce sperinatoxic condition in her blood and The solution thus produced and tested will be secretions. Other uses of the product will be useful in the process of ascertaining the presence apparent to the medical profession and others of human sperm and semen and safe-for vaccinaskilled in the art. i tion of women and effective in producing a 20 Spermatoxic vaccines eflective only upon the spermatoxic. condition, useful where undesired species from which obtained, have been produced on pti n n ay nd e r health d for h r and used. Such vaccines are practicallylimited] purposes obvious to the medical profession and 2 it; l'abtlratolry or egrperimentil use and becrause of otl firs fikfied infttllile art. t b0 d- 4 med 5 e na ura ando vious limi a. ions upont esupe 6 e 0 8 mix 1 a V6 9501 ply of materialv the production of such vaccines is essential to the rendering of the product nonfrom humans for use upon humans is impr tical, Specific- For the sam reason rod ti from m The isotonic solution is preferable to water or 7 sources, of sub tan e b ed f r determining other non-isotonic solution because it is more presence of perm or semen, is likewise lmnmceilicient in the extraction of the desired material tical. l v a from the testicular matter and because it reduces The present invention provides for the extraci a fuscomfort attendant upon the tion of the testiculars ermatozoa from'fresh Y mammalian testicularxstr uctures, subjecting the The addition of antiseptic not gssenua'l to same to a process wmch"whne preserving the the effectiveness of the product but is necessary spermatozoa and rendering it practically free g; in case of the use of the product on from injurious substances results in i e prege riative is not essential to the effecgg ifig g x fig ggzggi gi gizfizfis tiveness of the-product but should be added when 4 the product is not to be used promptly after pro- 40 when appliedto thehuman female by vaccination, duction p I p mg nven on proceed as o tion. The blood of the animal will then be used in a solution of or containing the matter to be mammals the tunica and connective tissue is tested. Precipitation from this solution indl-- removed by dissection- The testicles are then cates the presence ofsperm or semen in the tested A m l grinder may be l dl matter. When using the preparation as a vacthis purpose. cine it is injected intra-muscularly, preferably in To t e, m s ra d' ma er al he i dd d the buttocks, the dose or treatment for the aver- 60 preferably about o e-h lf y V ume f lq 1 d. age person being four injections live to seven preferably an isotonic solution such as Ringer's days apa t using 2 ccs. for the first injection, 8

or salt solution. .The mixture is then, finely ccs. for the second and 10 cos. each for the third ground, as in a mortar with seasand, until it-is and fourth injections. Number of injections insmooth and homogeneous after which it is heated creased in case of larger persons.

' ing the Variations of detail in the steps of the process and in the structure of the product. within the spirit and scope of the foregoing specification and appended claims will occur to those skilled in the art and I do not wish to be limited to the details of the herein described process and/or product.

I claim:

1. A spermatoxic vaccine containing mammalian spermatozoa renderednon-specific by heat.

2; A spermatoxic vaccine containing mammalian spermatozoawhich has been rendered'no'rb specific by heating to between 50 and 100 degrees ,C.

3. A spermatoxic vaccine containing a mixture of mammalian spermatozoa and a liquid harmless to humans when sub-cutaneously injected, the spermatozoa having been rendered non-specific by heat.

4. A spermatoxic vaccine containing a mixture of mammalian spermatozoa and an isotonic solution, the spermatozoa having been rendered nonspecific by heating to between 50 and 100 degrees C.

5. A spermatoxic vaccine containing a liquid harmless to humans when sub-cutaneously injected and mammalian spermatozoa rendered non-specific by heat, and an antisepticharmless to humans when sub-cutaneously injected.

6. The process of producing spermatoxic vac cine comprising obtaining the spermatozoa from mammalian testicles, adding a liquid harmless to humans. when sub-cutaneously injected, rendermixture homogeneous, heating the mixture to render the spermatozoa non-specific.

V 7. The process of producing spermatoxic vaccine comprising obtaining the spermatozoa irom mammalian testicles, adding approximately onehalf by volume of liquid harmless to humans when sub-,cutaneously ini ected; rendering the mixture homogeneous, heating the mixture to render the spermatozoa non-specific. r

8. The process of producing spermatoxic vaccine comprisingobtaining the spermatozoa from mammalian testicles, adding a liquid harmless to humans when sub-cutaneously injected, rendering the mixture homogeneous, heating the mixture to between 50 and 100 degrees C.

9. The process of producing spermatoxic vaccine comprising obtaining the spermatozoa from mammalian testicles, adding an isotonic solution ,thereto, rendering the mixture homogeneous,

heating the mixture to between 50 and 100 degrees C. a

' 10. A spermatoxic vaccine containing a mixture of mammalian spermatozoa and an isotonic solution, the spermatozoa having been rendered non-specific by heat.

I1. The process of producing a spermatoxic vaccine comprising obtaining mammalian spermatozoa and heating the same torender the spermatozoa non-specific.

12. The. process of producing a spermatoxic vaccine comprising obtaining mammalian spermatozoa and heating the same to between and degrees C.

' MORRIS J. BASKIN. 

